• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model

tetano

Editor, Senior Moderator
J Virol. 2014 Mar 12. [Epub ahead of print]
Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model.
Price GE1, Lo CY, Misplon JA, Epstein SL.
Author information
Abstract

Pandemic influenza is a major public health concern, but conventional strain-matched vaccines are unavailable early in a pandemic. Candidate "universal" vaccines targeting viral antigens nucleoprotein (NP) and matrix 2 (M2), which are conserved among all influenza A virus strains and subtypes, could be manufactured in advance for use at the onset of a pandemic. These vaccines do not prevent infection, but can reduce disease severity, deaths, and virus titers in the respiratory tract. We hypothesized that such immunization may reduce virus transmission from vaccinated, infected animals. To investigate this hypothesis, we studied mouse models for direct contact and airborne transmission of H1N1 and H3N2 influenza viruses. We established conditions under which virus transmission occurs, and showed that transmission efficiency is determined in part at the level of host susceptibility to infection. Our findings indicate that virus transmission between mice has both airborne and direct contact components. Finally, we demonstrated that immunization with recombinant adenovirus vectors expressing NP and M2 significantly reduced transmission of virus to co-housed, unimmunized mice in comparison to controls. These findings have broad implications for the impact of conserved antigen vaccines, not only in protecting the vaccinated individual but also in protecting others by limiting influenza virus transmission and potentially reducing the size of epidemics.
IMPORTANCE:

Using a mouse model of influenza A virus transmission, we demonstrate that a candidate "universal" influenza vaccine both protects vaccinated animals from lethal infection and reduces transmission of virus from vaccinated to non-vaccinated mice. This vaccine induces immunity against proteins conserved between all known influenza A virus strains and subtypes, so it could be used early in a pandemic before conventional strain-matched vaccines are available and could potentially reduce spread of infection in the community.

PMID:
24623430
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24623430
 
Back
Top Bottom